

Press release from Emotra AB (publ)

Göteborg, April 6, 2020

## **EMOTRA AB: Trade in subscription warrants on Spotlight Stock Market**

**In March 2020, EMOTRA AB (“Emotra”) carried out a rights issue of Units (where each unit comprises two (2) shares and (2) subscription warrants). This new issue was also open to the public.**

**The subscription warrants, series 2020, will be available for trade on the Spotlight Stock Market on April 20, 2020.**

11,653,840 shares were registered with Bolagsverket (The Swedish Companies Registration Office) on April 2, 2020, and we expect these shares to be distributed to the respective accounts/deposits of securities on April 16, 2020. After registration with Bolagsverket, the total number of Emotra shares is 38,043,599. After the rights issue, the share capital will amount to 722,828.38 SEK.

### **Summary of terms for subscription warrants**

**Subscription price:** Each subscription warrant grants its owner the right to subscribe for one (1) new share in the Company at a minimum price of 0.40 SEK per share and a maximum of 0.80 SEK per share.

**Subscription period:** Warrant-based share subscriptions will take place from October 9 to October 23, 2020. The subscription is executed by simultaneously depositing the cash amount due no later than 3 p.m. on Friday, October 23, 2020.

**Final trading day:** The final trading day for subscription warrants is scheduled for October 21, 2020.

**When fully subscribed:** If fully utilised, the subscription warrants will increase the share capital by a further 221,422.96 SEK, to a total of 944,251.34 SEK, and increase the total number of outstanding shares by 11,653,840 shares to 49,697,439 shares.

### **Project leader**

Emotra’s project leader in connection with the now completed rights issue was Mangold Fondkommission.

### **For further information about Emotra, please contact:**

Daniel Poté, CEO

Telephone: +46 732 34 41 93

E-mail: [daniel@emotra.se](mailto:daniel@emotra.se)

---

*EMOTRA AB is a medical technology company that carries out research, development, clinical studies and marketing in the area of mental health. The Company’s method, EDOR®, is a proprietary and objective psychophysiological test for detecting if patients suffering from depression are hyporeactive.*